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OBJECTIVE—Diabetesisaccompaniedwithachroniclow-gradeinﬂammation,whichmayin
part be mediated by endotoxins derived from Gram-negative bacteria.
RESEARCH DESIGN AND METHODS—We investigated in a population-based cohort
whether endotoxemia is associated with clinically incident diabetes. The serum endotoxin ac-
tivity was measured by limulus assay from the FINRISK97 cohort comprising 7,169 subjects
aged 25–74 years and followed up for 10 years.
RESULTS—Both the subjects with prevalent diabetes (n = 537) and those with incident di-
abetes(n=462)hadhigherendotoxinactivitythanthenondiabeticindividuals(P,0.001).The
endotoxin activity was signiﬁcantly associated with increased risk for incident diabetes with a
hazard ratio 1.004 (95% CI 1.001–1.007; P = 0.019) per unit increase resulting in a 52% in-
creasedrisk(P=0.013)inthehighestquartilecomparedwiththelowestone.Theassociationwas
independent of diabetes risk factors: serum lipids, g-glutamyl transferase, C-reactive protein,
BMI, and blood glucose. Furthermore, the association of endotoxemia with an increased risk of
incident diabetes was independent of the metabolic syndrome as deﬁned either by the National
Cholesterol Educational Program-Adult Treatment Panel III or the International Diabetes Fed-
eration. Endotoxin activity was linearly related (P , 0.001) to the number of components of the
metabolic syndrome.
CONCLUSIONS—Both prevalent and incident diabetes were associated with endotoxemia,
which may link metabolic disorders to inﬂammation. The results suggest that microbes play a
role in the pathogenesis of diabetes.
Diabetes Care 34:392–397, 2011
E
ndotoxin (lipopolysaccharide[LPS])
is one of the potent virulence factors
of Gram-negative bacterial species
and has a major role in both acute and
chronic infections. This unique glyco-
lipid is located at the outer membrane
of the bacteria, but in the circulation
system 80–97% of it is bound to the lip-
oproteins (1). LPS may be cleared from
the circulation system mainly by HDLs,
which also neutralize its activity effec-
tively.
Circulating endotoxin may derive
from bacteria causing either overt acute
infections or common chronic condi-
tions. Additionally, endotoxin is believed
to translocate from microbiota in the gut.
Experiments in animal models kept in
germ-free environments have shown that
endotoxin is associated with cardiometa-
bolic abnormalities including obesity, in-
sulin resistance, and diabetes (2).
Endotoxinactivates both adaptiveandin-
nate immune systems characterized
by a release of antibodies, cytokines, and
other inﬂammatory mediators, which
may promote hepatic insulin resistance.
Treatment of rats with an antibiotic spe-
ciﬁcally targeted against Gram-negative
bacteria reduces macrophage tumor ne-
crosis factor-a expression and hepatic
steatosis (3).
In humans, energy-enriched diets in-
creasing weight gain and insulin resis-
tance associate with absorption of
endotoxin from the gastrointestinal track
(4–6). This “metabolic endotoxemia” (7)
resulting from the increased intestinal
permeability/motility may lead to low-
grade inﬂammation. Severity of inﬂamma-
tion may depend on a complex interplay
between speciﬁc proteins, receptors, and
lipoproteins that mediate the endotoxin
bioactivity and metabolic fate.
In two small case-control studies,
circulating LPS was higher in both type
1 and type 2 diabetic subjects compared
with nondiabetic subjects (8,9). High se-
rum LPS activity also associates with the
development of diabetic nephropathy in
patients with type 1 diabetes (10). It has
been hypothesized that bacterial endo-
toxins can act as triggers, linking inﬂam-
mation to metabolic syndrome and
thereby diabetes (4,11,12). Studies of
this association in humans, however,
are scarce as a result of the methodo-
logical challenges. Therefore, we inves-
tigated in a large population-based
cohort followed up for 10 years, if endo-
toxemia is associated with clinically in-
cident diabetes.
RESEARCH DESIGN AND
METHODS—The FINRISK97 involved
a population-based sample (n = 7,169)
of 25- to 74-year-old participants of the
survey, which was conducted in ﬁve geo-
graphicalareasinFinland(13).Thesurvey
included a self-administered question-
naire and a clinical examination with
weight, height, and blood pressure mea-
surements as well as blood drawing. The
study was approved by the Ethics Com-
mittee of the National Public Health Insti-
tute and conducted according to the
Helsinki Declaration. All subjects gave
written informed consent.
Laboratory analyses
Before blood sampling, the participants
were asked to fast for 4 h and to avoid
heavy meals earlier during the day. The
median fasting time was 5 (interquartile
range 3–7) hours. All laboratory mea-
surements, except serum glucose (14),
were carried out at the Disease Risk
Unit in the National Institute for
Health and Welfare, Helsinki. Lipids and
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ORIGINAL ARTICLEg-glutamyltransferase (GGT) measure-
ments were performed from fresh serum
samples on clinical chemistry analyzers:
Olli-C (Thermo Scientiﬁc, Vantaa, Fin-
land)in1997andultrasensitiveC-reactive
protein (CRP) from frozen samples
(270°C)onArchitectc8000analyzer(Ab-
bott Laboratories, Abbott Park, IL) in
2005. Total cholesterol, triglyceride, and
GGT concentrations were determined en-
zymatically using commercial reagents
(Thermo Scientiﬁc). HDL cholesterol
concentration was measured after precip-
itation of apolipoprotein B-containing
lipoproteinswithdextransulfateandmag-
nesium chloride. CRP was measured
using a latex immunoassay (Sentinel diag-
nostics,Milan,Italy).LDLcholesterolcon-
centrations were calculated according to
the Friedewald formula. For standardiz-
ing the measurements, the laboratory
has taken part in the World Health
Organization Lipid Reference Program
(Prague) and External Quality Assess-
ment Schemes organized by Labquality
(Helsinki, Finland).
Serum endotoxin activities were de-
termined by kinetic Limulus Amebosyte
Lysate (LAL) test kit with a chromogenic
substrate (HyCult biotechnology b.v.,
Uden, the Netherlands) on diluted (1:5,
vol/vol in endotoxin-free water) samples.
The interassay coefﬁcient of variation was
9.2% (n =7 5 ) .
Diabetes at baseline and follow-up
Baseline diabetes was deﬁned either
from 1) the questionnaire as a doctor-
diagnosed disease or impaired glucose
tolerance, 2) the drug reimbursement re-
cords of purchases of hypoglycemic
drugs (ATC-class A10) from the Social
Insurance Institution of Finland (SII), 3)
the SII records of patients entitled to re-
imbursed diabetes medication, or 4)t h e
National Hospital Discharge Register for
hospitalizations with diabetes (E10-E14/
ICD-10; 250/ICD-9) as the main or addi-
tional diagnosis.
The follow-up of the cohort was until
the end of the year 2007. The cases with
incident diabetes were identiﬁed from 1)
the drug reimbursement records of hypo-
glycemic drugs (ATC-class A10) from SII,
2) the SII records of patients entitled to
reimbursed diabetes medication, 3)t h e
National Hospital Discharge Register for
hospitalizationswithdiabetes(ICD-codes
as above), and 4) the National Causes-of-
Death Register with diabetes (ICD-codes
as above) astheunderlying, directorcon-
tributing cause of death.
Deﬁnitions of metabolic syndrome
The nondiabetic subjects were classiﬁed
into those with and without metabolic
syndrome using two deﬁnitions: 1)t h e
National Cholesterol Educational Program-
Adult Treatment Panel III (ATP III) (15)
and 2) the International Diabetes Federa-
tion (16). Missing glucose concentrations
(n = 941, 14%) were substituted with the
mean observed value, 5.12 mmol/L, and
used in the calculations of the prevalence
of metabolic syndrome.
Statistics
The statistical signiﬁcance of the differ-
ences between the subjects with and
without diabetes was tested with t test or
x
2 test. The values with skewed distribu-
tion, serum triglyceride and CRP concen-
trations, and endotoxin activities, were
log-transformed before comparisons.
Bivariate correlations were examined
by a two-tailed Pearson correlation anal-
yses.Smokinghabitwasusedinthreecat-
egories: never, former, and current.
Hypertension was deﬁned according to
the American Heart Association def-
inition, if the systolic or diastolic blood
pressure exceeded 140 and 90 mmHg,
respectively, or if the subject was on
medication for hypertension. Years of
education was used to describe the socio-
economic status. Family history of dia-
betes (either the mother or the father)
and free-time physical inactivity (level 1
on a scale of 1–4) were obtained from the
questionnaires. The association of serum
endotoxinactivitywithprevalentdiabetes
was analyzed using a logistic regression
model adjusted for age and sex.
The association of endotoxin activity
withincidentdiabeteswasanalyzedusing
Table 1—Baseline risk factors of the subjects with and without incident diabetes
No diabetes
(n = 6,170)
Incident diabetes
(n = 462)
Mean (SD) P*
Age (years) 53.2 (11.0) 57.3 (9.4) ,0.001
Education (years) 10.8 (4.0) 9.4 (3.5) ,0.001
Cholesterol (mmol/L) 5.7 (1.0) 5.9 (1.1) ,0.001
HDL cholesterol (mmol/L) 1.40 (0.36) 1.21 (0.33) ,0.001
Triglycerides (mmol/L)†
Determined 1.48 (0.95) 2.19 (1.30) ,0.001
Corrected for fasting time 1.34 (0.85) 2.01 (1.18) ,0.001
LDL cholesterol (mmol/L) 3.61 (0.91) 3.81 (0.94) ,0.001
G-GT (U/L)† 36.4 (58.6) 58.1 (112) ,0.001
CRP (mg/L)† 2.47 (5.17) 4.57 (8.02) ,0.001
Glucose (mmol/L)
Determined (n = 5,691) 5.06 (0.63) 5.84 (1.92) ,0.001
Missing values replaced (n = 6,632) 5.08 (0.51) 5.59 (1.58) ,0.001
Endotoxin (EU/mL)† 61.06 (36.11) 77.03 (42.03) ,0.001
BMI (kg/m
2) 2 6 . 7( 4 . 1 ) 3 1 . 6( 5 . 2 ) ,0.001
Waist (cm) 89.0 (12.7) 102.9 (13.3) ,0.001
Waist-to-hip ratio 0.87 (0.09) 0.94 (0.09) ,0.001
Systolic blood pressure (mmHg)‡ 138.3 (20.4) 148.3 (20.0) ,0.001
Diastolic blood pressure (mmHg)‡ 83.8 (10.8) 88.7 (11.5) ,0.001
n (%) P§
Male 2,962 (50.5) 261 (60.1) ,0.001
Female 2,900 (49.5) 173 (39.9)
Smoking
Never 3,321 (53.8) 234 (50.6) 0.374
Former 1,507 (24.4) 117 (25.3)
Current 1,342 (21.8) 111 (24.0)
Hypertensive 3,080 (50.0) 341 (73.8) ,0.001
Family history of diabetes 1,278 (20.7) 129 (27.9) ,0.001
Free-time physical inactivity 1,271 (20.6) 169 (36.6) ,0.001
Metabolic syndrome (ATP-III) 1,175 (20.1) 269 (62.0) ,0.001
Metabolic syndrome (IDF) 1,455 (24.9) 287 (66.1) ,0.001
*t test. †Log transformation before comparisons. ‡Mean value of two measurements. §x
2 test.
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age and sex, then for diabetes risk factors
(education, smoking, hypertension, fam-
ily history of diabetes, free-time physical
inactivity, and BMI, as well as serum
cholesterol,triglyceride,HDLcholesterol,
GGT, and CRP concentrations), and fur-
ther for serum glucose concentrations
(determined values only, n = 5,691).
Both semifasting serum triglyceride con-
centrations determined and calculated
fasting triglyceride concentrations (17)
were accounted for in separate models.
In another Cox model, metabolic syn-
dromedeﬁned as described above was in-
cluded as a covariate together with age,
sex,smokinghabit,education,familyhis-
tory of diabetes, free-time physical inac-
tivity, and GGT and CRP concentration.
Linear trend of endotoxin activity versus
number of positive metabolic syndrome
parameters was tested using ANOVA
with linear contrasts and assuming equal
variances. The statistical analyses were
performed using SPSS 15.0.
RESULTS—The FINRISK97 cohort in-
cluded 537 (7.9%) subjects with preva-
lent diabetes at baseline. Their mean (SD)
serum endotoxin activity was higher than
that in nondiabetic subjects, 70.73
(42.62) vs. 62.18 (36.77) EU/mL, P ,
0.001, respectively. This produced odds
ratios (95% CI) of 1.005 (1.003–1.008,
P , 0.001)/unit increase, or 1.043 (0.759–
1.433, P = 0.79), 1.717 (1.290–2.284, P ,
0.001), and 2.232 (1.689–2.949, P ,
0.001) for prevalent diabetes in the 2nd,
3rd, and 4th quartile of serum endotoxin
activity compared with the 1st quartile
when adjusted for age and sex. These sub-
jects were excluded from further analyses.
Serum endotoxin activity had a sig-
niﬁcant positive correlation with CRP,
cholesterol, and triglyceride concentra-
tion, and a negative correlation with HDL
cholesterol concentration. It did not cor-
relate with the fasting time. Character-
istics of those with (n = 462) and without
(n = 6,170) incident diabetes during the
median follow-up time of 10.8 years are
summarized in Table 1. The risk factors
associatedwith diabetes and cardiovascu-
lar diseases accumulated in those with in-
cident diabetes: all differences were
highlysigniﬁcantexceptthatofthesmok-
ing habit. Also serum endotoxin activity
was higher (P , 0.001) in those who de-
v e l o p e dd i a b e t e sc o m p a r e dw i t ht h o s e
who did not. It was signiﬁcantly associ-
ated with increased risk for diabetes
with a hazard ratio (HR) (95% CI) of
1.008 (1.006–1.010, P , 0.001)/unit,
when adjusted for age and sex, and
1.004 (1.001–1.007, P = 0.019)/unit,
when adjusted for diabetes risk factors.
The regression models for endotoxin
quartiles are shown in the table (Table 2,
Fig. 1). Replacing determined semifasting
triglyceride concentrations with calculated
fasting triglyceride concentrations or add-
ing glucose concentrations into the model
did not notably change the results.
According to ATP III and IDF deﬁni-
tions, 1,444 (23.0%) and 1,742 (27.7%)
hadmetabolicsyndrome,whichwasmore
prevalent in those with incident diabetes
than in those without (Table 1). Serum
endotoxin activity increased linearly
(P , 0.001) in the categories of positive
metabolic syndrome parameters (Fig. 2).
In a Cox regression model, it remained
signiﬁcantly associated with an increased
risk for incident diabetes, when the
presence of metabolic syndrome was
introduced as a covariate: the HRs in
the highest endotoxin quartiles were
1.650 (95% CI 1.210–2.250, P = 0.002)
(Table 3) and 1.701 (1.249–2.316, P =
0.001) depending on the metabolic
syndrome deﬁnition, ATP III or IDF,
respectively.
CONCLUSIONS—In this large pro-
spective cohort we show that endotoxe-
mia is associated with increased risk for
clinically incident diabetes. Importantly,
the risk was independent of established
diabetes risk factors, i.e., glucose, lipid,
and CRP levels, as well as BMI. It was also
independent of factors known to affect
serum endotoxin activity, i.e., choles-
terol, triglyceride, and HDL cholesterol
concentrations, as well as smoking
(10,18). Interestingly, despite the linear
relation between endotoxemia and the
Table 2—Associations between risk factors and incident diabetes
95% CI
HR Lower bound Upper bound Signiﬁcance
Model 1
Age (years) 1.046 1.036 1.056 ,0.001
Male 1.382 1.139 1.678 0.001
Endotoxin quartiles* 1.000 ,0.001†
Q1
Q2 1.073 0.768 1.498 0.681
Q3 1.703 1.255 2.309 0.001
Q4 2.751 2.071 3.654 ,0.001
Model 2
Age (years) 1.040 1.028 1.053 ,0.001
Male 1.194 0.938 1.520 0.150
Education (years) 0.989 0.958 1.022 0.512
Family history of diabetes 1.481 1.187 1.848 0.001
Free-time physical inactivity 1.370 1.094 1.715 0.006
Cholesterol (mmol/L) 1.098 0.983 1.226 0.097
HDL (mmol/L) 0.438 0.292 0.659 ,0.001
Smoking
Never 1.000 0.062†
Former 0.994 0.768 1.288 0.965
Current 1.335 1.028 1.734 0.030
Triglycerides (mmol/L) 1.090 0.994 1.194 0.066
GGT (U/L) 1.001 1.000 1.002 0.001
BMI (kg/m
2) 1.149 1.128 1.171 ,0.001
Hypertensive 0.869 0.708 1.067 0.179
CRP (mg/L) 1.017 1.005 1.030 0.007
Endotoxin quartiles*
Q1 1.000 0.012†
Q2 0.939 0.652 1.351 0.733
Q3 1.233 0.885 1.718 0.216
Q4 1.518 1.090 2.114 0.013
*Endotoxin quartiles: Q1 2.40–38.10 EU/mL, Q2 38.20–54.10 EU/mL, Q3 54.20–77.0 EU/mL, Q4 77.10–
475.8 EU/mL. †P for trend.
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Endotoxemia and diabetesnumber of parameters deﬁning the meta-
bolic syndrome, high serum endotoxin
activity was still associated with an in-
creased diabetes risk.
Endotoxins can be found in the
serum of apparently healthy subjects
(19) because in common chronic infec-
tions and subclinical conditions the
Gram-negative organisms colonize the
humanrespiratory,genitourinary,andes-
peciallythegastrointestinaltract,including
the oral cavity and the gut. For example,
endotoxemia may arise from the most
common chronic oral infection, perio-
dontitis, which has an association with
incident cardiovascular disease events
and type 2 diabetes (18,20). The limulus
assay used presently does not reveal the
source of the endotoxin activity which
varies greatly between bacterial clones.
The assay is not speciﬁc to any bacterial
species, but responds to the initial phase
of the complement activation by LPS.
Latest evidence suggests, however, that
bacterial LPS deriving from the gut mi-
crobiota may trigger inﬂammation and
oxidative stress in response to diets
(4,6,21–23). High intake of fat or carbohy-
dratesdoesnotpromoteonlyendotoxemia,
but also production of LPS transporting
proteins and receptors (23). This “meta-
bolic endotoxemia” has been shown to
initiate or promote obesity, insulin resis-
tance, metabolic syndrome, and ﬁnally
diabetes (5). Whatever the sources, the
currentstudyclearlyindicatesfortheﬁrst
time an association between endotoxemia
and incident diabetes.
The metabolic fate of endotoxins is
highly dependent on serum lipoprotein
balance, although it is bound by all
lipoprotein classes (1). LPS mainly binds
to HDL in health but to VLDL in sepsis,
thereby increasing its afﬁnity to lipopro-
teins with lower density during an infec-
tion (1,24). Dietary fat is incorporated
from the gut into triglyceride-enriched
lipoproteins, chylomicrons, whose forma-
tion promotes LPS absorption (23,25).
This is in accordance with our present
observation that endotoxin activity has
a strong positive correlation with serum
triglyceride concentration, as also re-
ported earlier (10,18). More basic re-
search, however, is needed to deﬁne the
role of chylomicron-associated LPS in
inﬂammation because the cellular re-
sponses also depend on the equilibrium
of multiple endotoxin receptors and
transfer proteins.
A clear limitation of the current study
is the use of semifasting serum samples in
the triglyceride, glucose, and endotoxin
determinations.Themeanrelativechange
in triglyceride concentration per fasting
hour is 23.7% (95% CI 24.2 to 23.1),
and the semifasting results can be con-
verted into fasting ones using a speciﬁc
factor for the fasting time (17). In the
current study, both semifasting and the
Figure 1—Cumulative survival without incident diabetes. The cumulative survival in LPS
quartiles was analyzed by Cox regression model adjusted for age, sex, education, family diabetes
history, free-time physical inactivity, smoking, hypertension, BMI, serum cholesterol, tri-
glyceride, HDL cholesterol, GGT and CRP concentrations. The HR and 95% CI for the quartiles
are shown in Table 2.
Figure2—Serumendotoxinactivitiesaccordingtonumberofparametersofmetabolicsyndrome.
Metabolic syndrome was deﬁned according to the ATP III criteria (n = 6,273), and mean endo-
toxin activities with 95% CI are shown. The number of subjects in the categories is 0 = 1,203, 1 =
2,118, 2 = 1,507, 3 = 934, 4 = 459, and 5 = 52. Linear trend of endotoxin activity vs. number of
positive metabolic syndrome parameters was tested using ANOVA with linear contrasts and
assuming equal variances.
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did not have an effect on the main result.
Glucose measurements were used in an
additional Cox model as a covariate, and
they did not affect the association between
endotoxemiaandincidentdiabetes,either.
Intheabsenceoffastingbloodglucoseval-
ues, however, we did not have a chance to
identifytheclinicallymildcasesofincident
diabetes, i.e., those treated with diet only,
which may have caused an underestima-
tion in the results. In addition, it may have
resulted in some misclassiﬁcations of sub-
jects with metabolic syndrome. Fasting
time may also affect plasma endotoxin
concentration (23), although in the cur-
rent study no such correlation was found.
The effect, however, is dependent on the
composition of the meal before (23)—
information which was not within the
scope of our study.
The expanding epidemic of diabetes
in industrialized countries requires more
research on its predictors. Our results
indicate for the ﬁrst time that endotox-
emia is a key player in the pathogenesis of
diabetes and that microbes may have a
central role.
Acknowledgments—Funding for this study
was obtained from the Academy of Finland
(Grant 118391 to P.J.P.), the Sigrid Juselius
Foundation (to P.J.P), and the Finnish Foun-
dation for Cardiovascular Research (to V.S.).
No potential conﬂicts of interest relevant to
this article were reported.
P.J.P. performed endotoxin laboratory mea-
surements and statistical analyses, interpreted
the data, and wrote the manuscript. A.S.H.
performed statistical analyses and collected
data. M.L. interpreted data. J.S. made labora-
tory determinations. V.S. designed the study,
collected and interpreted data, and wrote the
manuscript.
References
1. Kallio KAE, Buhlin K, Jauhiainen M, et al.
Lipopolysaccharide associates with pro-
atherogenic lipoproteins in periodontitis
patients. Innate Immun 2008;14:247–253
2. Turnbaugh PJ, Ley RE, Mahowald MA,
Magrini V, Mardis ER, Gordon JI. An
obesity-associated gut microbiome with
increased capacity for energy harvest.
Nature 2006;444:1027–1031
3. Pappo I, Becovier H, Berry EM, Freund
HR. Polymyxin B reducescecalﬂora, TNF
production and hepatic steatosis during
total parenteral nutrition in the rat. J Surg
Res 1991;51:106–112
4. Cani PD, Amar J, Iglesias MA, et al. Met-
abolic endotoxemia initiates obesity and
insulin resistance. Diabetes 2007;56:
1761–1772
5. Cani PD, Neyrinck AM, Fava F, et al. Se-
lective increases of biﬁdobacteria in gut
microﬂora improve high-fat-diet-induced
diabetes in mice through a mechanism
associatedwithendotoxaemia.Diabetologia
2007;50:2374–2383
6. Amar J, Burcelin R, Ruidavets JB, et al. En-
ergy intake is associated with endotoxemia
in apparently healthy men. Am J Clin Nutr
2008;87:1219–1223
7. DiBaise JK, Zhang H, Crowell MD,
Krajmalnik-BrownR,DeckerGA,Rittmann
BE. Gut microbiota and its possible re-
lationship with obesity. Mayo Clin Proc
2008;83:460–469
8. Devaraj S, Dasu MR, Park SH, Jialal I. In-
creased levels of ligands of Toll-like re-
ceptors 2 and 4 in type 1 diabetes.
Diabetologia 2009;52:1665–1668
9. Creely SJ, McTernan PG, Kusminski CM,
et al. Lipopolysaccharide activates an in-
nate immune system response in human
adipose tissue in obesity and type 2 di-
abetes. Am J Physiol Endocrinol Metab
2007;292:E740–E747
10. Nymark M, Pussinen PJ, Tuomainen AM,
Forsblom C, Groop PH, Lehto M; Finn-
Diane Study Group. Serum lipopolysac-
charide activity is associated with the
progression of kidney disease in ﬁnnish
patients with type 1 diabetes. Diabetes
Care 2009;32:1689–1693
11. Erridge C, Attina T, Spickett CM, Webb
DJ. A high-fat meal induces low-grade
endotoxemia: evidence of a novel mech-
anismofpostprandialinﬂammation.AmJ
Clin Nutr 2007;86:1286–1292
12. Manco M. Endotoxin as a missed link
among all the metabolic abnormalities in
the metabolic syndrome. Atherosclerosis
2009;206:36; author reply 37
13. Vartiainen E, Laatikainen T, Peltonen M,
et al. Thirty-ﬁve-year trends in cardio-
vascular risk factors in Finland. Int J Epi-
demiol 2010;39:504–518
14. Salomaa V, Havulinna A, Saarela O, et al.
Thirty-onenovelbiomarkersaspredictors
for clinically incident diabetes. PLoS ONE
2010;5:e10100
15. Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol
in Adults. Executive Summary of The
Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel
on Detection, Evaluation, And Treatment
of High Blood Cholesterol In Adults
(Adult Treatment Panel III). JAMA 2001;
285:2486–2497
16. Alberti KG, Eckel RH, Grundy SM, et al.;
International Diabetes Federation Task
Force on Epidemiology and Prevention;
HationalHeart,Lung,andBloodInstitute;
AmericanHeartAssociation;WorldHeart
Federation; International Atherosclerosis
Society; International Association for
the Study of Obesity. Harmonizing the
metabolic syndrome: a joint interim
statement of the International Diabetes
Federation Task Force on Epidemiology
and Prevention; National Heart, Lung,
and Blood Institute; American Heart
Association; World Heart Federation;
InternationalAtherosclerosisSociety;and
International Association for the Study
Table 3—Associations of serum endotoxin activity with incident diabetes when metabolic
syndrome is included as a covariate
95% CI
HR Lower bound Upper bound Signiﬁcance
Age (years) 1.028 1.016 1.039 ,0.001
Male 1.243 1.003 1.541 0.047
Education (years) 0.959 0.929 0.990 0.010
Family history of diabetes 1.397 1.122 1.738 0.003
Free time physical inactivity 1.744 1.414 2.151 ,0.001
Smoking
Never 1.000 0.309*
Former 1.047 0.817 1.342 0.718
Current 1.218 0.944 1.571 0.130
CRP (mg/L) 1.023 1.014 1.033 ,0.001
GGT (U/L) 1.001 1.000 1.001 0.002
Metabolic syndrome† 4.228 3.402 5.255 ,0.001
Endotoxin quartiles‡
Q1 1.000 ,0.001*
Q2 0.909 0.636 1.297 0.598
Q3 1.329 0.960 1.841 0.086
Q4 1.650 1.210 2.250 0.002
*P for trend. †According to ATP III deﬁnition. ‡Endotoxin quartiles: Q1 2.40–38.10 EU/mL, Q2 38.20–
54.10 EU/mL, Q3 54.20–77.0 EU/mL, Q4 77.10–475.8 EU/mL.
396 DIABETES CARE, VOLUME 34, FEBRUARY 2011 care.diabetesjournals.org
Endotoxemia and diabetesof Obesity. Circulation 2009;120:1640–
1645
17. Sundvall J, Laatikainen T, Hakala S,
Leiviskä J, Alfthan G. Systematic error of
serum triglyceride measurements during
three decades and the effect of fasting on
serum triglycerides in population studies.
Clin Chim Acta 2008;397:55–59
18. Pussinen PJ, Tuomisto K, Jousilahti P,
Havulinna AS, Sundvall J, Salomaa V.
Endotoxemia, immune response to peri-
odontal pathogens, and systemic inﬂamma-
tion associate with incident cardiovascular
disease events. Arterioscler Thromb Vasc
Biol 2007;27:1433–1439
19. Pussinen PJ, Vilkuna-Rautiainen T, Alfthan
G, et al. Severe periodontitis enhances
macrophage activation via increased serum
lipopolysaccharide. Arterioscler Thromb
Vasc Biol 2004;24:2174–2180
20. Demmer RT,Jacobs DR Jr, Desvarieux M.
Periodontal disease and incident type 2
diabetes: results from the First National
Health and Nutrition Examination Sur-
vey and its epidemiologic follow-up
study. Diabetes Care 2008;31:1373–
1379
21. Grunfeld C, FeingoldKR.Endotoxin inthe
gut and chylomicrons: translocation or
transportation? J Lipid Res 2009;50:1–2
22. Deopurkar R, Ghanim H, Friedman J,
et al. Differential effects of cream, glu-
cose, and orange juice on inﬂammation,
endotoxin, and the expression of Toll-like
receptor-4 and suppressor of cytokine sig-
naling-3. Diabetes Care 2010;33:991–997
23. Ghanim H, Sia CL, Upadhyay M, et al.
Orangejuiceneutralizestheproinﬂammatory
effect of a high-fat, high-carbohydrate meal
and prevents endotoxin increase and Toll-
like receptor expression. Am J Clin Nutr
2010;91:940–949
24. Levine DM, Parker TS, Donnelly TM,
Walsh A, Rubin AL. In vivo protection
against endotoxin by plasma high density
lipoprotein.ProcNatlAcadSciUSA1993;
90:12040–12044
25. Ghoshal S, Witta J, Zhong J, de Villiers W,
Eckhardt E. Chylomicrons promote in-
testinal absorption of lipopolysaccharides.
J Lipid Res 2009;50:90–97
care.diabetesjournals.org DIABETES CARE, VOLUME 34, FEBRUARY 2011 397
Pussinen and Associates